Albendazol MK

Albendazole

Method of action: Anthelmintic

Treatment option: Pork Tapeworm Infection, Neurocysticercosis, Echinococcus, Hydatid Disease

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Albendazol MK

Quick Facts

Property	Description
Active Ingredient	Albendazole
Form	Tablet / Oral Suspension
Pharmacological Class	Anthelmintic / Benzimidazole Carbamate
General Purpose	Systemic anti-worm medication
Origin	Synthetic (Small Molecule)

What is Albendazol MK and its Pharmacological Classification?

Albendazol MK is a prescription-only pharmaceutical preparation containing the active chemical substance, Albendazole, which is definitively classified as an anthelmintic agent. This medication belongs to the benzimidazole carbamate pharmacological group, defining it as a specialized, single-agent product used for the systemic management of helminth infections caused by parasitic worms. The drug is clinically recognized by public health organizations, and its established importance is underscored by its inclusion on the WHO Model List of Essential Medicines.

Composition, Origin, and Available Forms

Albendazole is a synthetic compound derived from the benzimidazole chemical structure, making it a small molecule drug. Albendazol MK is typically supplied in solid oral dosage forms, such as the tablet, but may also be available as an oral suspension, a form often used for ease of administration to specific patient groups, such as children. These preparations are designed solely for the oral route of administration, allowing the drug to be absorbed into the body where it can exert its effects.

The Basic Principle: How Does Albendazole Serve Its Purpose?

The basic principle behind Albendazole's function is to eliminate parasitic organisms by causing their internal collapse and starvation. The medication works by selectively binding to the parasite's internal structures, specifically inhibiting a crucial process called tubulin polymerization, which leads to a critical depletion of the worm’s energy supply. This targeted action ensures the worm becomes immobilized and eventually dies. The general purpose of the drug is thus to act as a broad-spectrum agent, efficiently and non-invasively clearing the body of the parasitic burden, such as in the typical use case of treating soil-transmitted helminth infections.

What side effects are possible with Albendazol MK?

Possible Side Effects and Safety Information

The safety profile of Albendazole, the active ingredient in Albendazol MK, is officially classified by frequency and by the body systems affected. The most common adverse reactions reported in regulatory documents include neurological and gastrointestinal effects, such as headache, dizziness, abdominal pain, nausea, and vomiting.

Adverse effects are documented across several System-Organ Classes, notably the Hepatobiliary Disorders and Blood and Lymphatic System Disorders. While uncommon, official labeling describes elevations in hepatic enzymes (liver function tests) and reductions in white blood cell count (leukopenia).

Serious adverse reactions, though rare, are documented and include severe bone marrow suppression (e.g., aplastic anemia, pancytopenia) and acute liver failure. The risk for these serious effects is noted to be greater with the longer duration of treatment and higher doses typically used for systemic infections. Conversely, issues like hair loss (alopecia) and mild to moderate liver enzyme elevations are generally described as reversible upon treatment cessation.

Official regulatory labels impose essential safety restrictions and monitoring requirements. The medicine is contraindicated in pregnancy due to regulatory evidence of potential harm. Furthermore, mandatory monitoring of both complete blood counts and liver function tests is required by authorities before and at regular intervals during therapy, particularly for prolonged treatment cycles.

Overdose and Emergency Response

A suspected overdose of Albendazol MK requires immediate medical attention. The official regulatory profile identifies the primary risks associated with excessive exposure as severe dose-dependent toxicities impacting crucial physiological systems.

Overdosage may be manifested by an exacerbation of common adverse reactions, including upper gastrointestinal symptoms and, in severe cases, potential neurological signs such as seizures. However, the most serious documented outcomes involve the hematopoietic system and the hepatic system. Excessive exposure can lead to severe bone marrow suppression, resulting in conditions such as leukopenia, pancytopenia, or agranulocytosis, with fatalities reported in association with these hematological toxicities. Elevated hepatic enzymes and the risk of acute liver failure are also noted regulatory concerns.

For patients with pre-existing liver disease, the official documentation suggests an increased susceptibility to these severe hematological effects.

As no specific antidote is known, the management of overdosage is strictly limited to providing symptomatic and supportive care, which may involve gastric lavage. Close and mandatory monitoring of blood counts and Liver Function Tests is required to manage and identify these documented life-threatening risks.

Therapeutic Uses of Albendazol MK

What Albendazol MK treats: main uses and benefits

Albendazol MK is a medication prescribed for the treatment of various helminth infections, which are caused by parasitic worms. Its use is primarily directed at addressing infections within the gastrointestinal tract and those that affect body tissues. This medicine is utilized to address major intestinal worm infections, including roundworm (Ascaris lumbricoides), hookworm (Necator americanus or Ancylostoma duodenale), and pinworm (Enterobius vermicularis). Its administration is associated with the relief of related symptoms, such as abdominal discomfort and other digestive issues.

The drug is also used for managing more complex tissue-based parasitic conditions, such as neurocysticercosis and cystic hydatid disease (Echinococcosis). These clinical scenarios involve parasitic activity in areas like the brain or organs, and the medication may assist in managing the parasitic load.

Quick Fact: Addresses intestinal worm infections

Eligibility and Restrictions for Use

Who Can and Cannot Use Albendazol MK?

The eligibility for Albendazol MK is strictly defined by regulatory documents, separating populations into approved, restricted, and contraindicated groups.

Contraindicated Populations

Use of Albendazol MK is prohibited for the following populations:

Pregnant Women: The medicine is formally contraindicated due to demonstrated risk of fetal harm.
Patients with Hypersensitivity: Individuals with a known allergy to Albendazole, other benzimidazole derivatives, or any non-active components of the formulation.

Age-Based and Conditional Restrictions

Population Group	Regulatory Status	Restriction Basis
Children under 2 years	Not Recommended	Limited clinical experience or safety data.
Women of Childbearing Age	Conditional Use	Must obtain a negative pregnancy test and use effective contraception during and for a specified period after treatment.
Patients with Liver Disease	Use with Caution	Requires close monitoring of liver function tests (LFTs) and blood cell counts due to risk of hepatotoxicity.
Breastfeeding Women	Not Recommended	Label advises discontinuation of breastfeeding during and after therapy.
Elderly Patients (65+)	Limited Experience	Caution required if underlying hepatic dysfunction is present.

Eligibility is generally approved for adults and children over 2 years of age who do not meet any contraindicated or conditional-use criteria. Patients with neurocysticercosis must undergo a retinal examination before starting treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile of Albendazol MK is defined by pharmacokinetic effects that significantly alter the systemic exposure of its active metabolite, Albendazole sulfoxide.

Interacting Substance	Official Interaction Effect
Dexamethasone	Increases the steady-state trough plasma concentrations of the active metabolite by approximately 56%.
Praziquantel	Increases the mean maximum plasma concentration (Cmax) and AUC of Albendazole sulfoxide by approximately 50%.
Cimetidine	Increases Albendazole sulfoxide concentrations in bile and cystic fluid up to two-fold.

Conversely, co-administration with enzyme-inducing anticonvulsants, including Phenytoin, Carbamazepine, and Phenobarbital, is documented to reduce the systemic exposure of the active metabolite due to enhanced drug metabolism. Albendazol MK may also induce Cytochrome P450 1A (CYP1A), leading to an official recommendation to monitor plasma levels of co-administered Theophylline.

In terms of pharmacodynamic effects, the concurrent use of Albendazol MK with other myelosuppressive agents carries the risk of additive myelosuppression.

Regarding substances, administration with a fatty meal significantly increases the systemic exposure and is a constraint defined in regulatory labeling. Additionally, Grapefruit juice is documented to increase the active metabolite's plasma concentration. Patients with hepatic impairment are officially noted to be at increased risk for adverse effects related to the medication.

Mechanism of Action

The mechanism of action of Albendazol MK is defined by selective interference with the biology of the target parasite. The drug's active metabolite acts as a molecular inhibitor by specifically binding to the beta-tubulin subunits within the helminth's cells. This binding prevents the polymerization of beta-tubulin, resulting in the depolymerization and subsequent collapse of essential microtubules that form the parasite's internal cytoskeleton. The loss of structural integrity leads to a critical disruption of key cellular functions, including the transport of materials and cell division. This cascade extends to the energy metabolic pathway, where the compromised structure impairs the parasite’s ability to absorb and utilize glucose, leading to a profound blockade of its energy metabolism. The resultant rapid systemic starvation and irreversible physiological failure lead directly to the death of the organism.

Dosage and Administration Information

Administration Guidelines for Albendazole

This section outlines the general use of albendazole. It is not clinical advice.

1. Administration Route and Conditions

Instruction Category	Detail
Route of Administration	Oral route (swallowed).
Administration Condition	Must be taken with food, particularly a fatty meal, to maximize the absorption of the medicine.

2. Dosage Forms and Schedule

Albendazole is available as tablets (e.g., 200 mg or 400 mg strength) and as an oral suspension. The dosing schedule is variable and depends on the infection being treated, ranging from a single 400 mg dose (for many intestinal parasites) to regimens requiring twice-daily (BID) dosing and multiple cycles.

Schedule Example	Frequency	Course Duration
Intestinal Infections	Single Dose or Daily	1 to 3 Days
Systemic Infections (e.g., Neurocysticercosis)	Twice Daily	8 to 30 Days
Hydatid Disease	Twice Daily	Multiple 28-day Cycles

3. Preparation and Use for Specific Groups

Tablets: The tablets may be crushed or chewed and swallowed with water if the patient has difficulty swallowing the tablet whole.
Suspension: The oral suspension must be shaken well before measuring the prescribed dose.
Pediatric Use: For children under two years, specific lower dosing may be indicated, and the suspension form is often required. Dosing for systemic infections may be weight-based, such as 15 mg/kg/day divided BID for patients weighing less than 60 kg.

Recent Clinical Evidence

Albendazol: Overview of Clinical Evidence

Clinical research and meta-analyses have focused on evaluating the efficacy and safety profile of albendazole, a broad-spectrum anthelmintic agent. Studies primarily investigate its role in treating parasitic infections, including neurocysticercosis (NCC) and hydatid disease, as well as common intestinal helminthiasis.

Efficacy Findings

Research has explored the association between albendazole use and changes in infection burden and clinical outcomes. In cases of neurocysticercosis, studies have examined whether the use of albendazole, often combined with corticosteroids, may be associated with a reduction in the number and size of cerebral lesions. Findings suggest that this regimen may be associated with improvements in seizure control in some individuals, particularly those with viable cysts.

For hydatid disease (Echinococcosis), clinical data has assessed the response of cysts to long-term albendazole therapy, frequently measured by changes in cyst viability or size as determined by imaging. Evidence remains limited, and outcomes are often heterogeneous, depending on the site and type of the cyst.

Safety and Tolerability

Safety data collected across multiple trials indicate that adverse events are generally dose-dependent and reversible. The most commonly reported side effects include mild, transient symptoms such as headache, nausea, and abdominal pain. Elevated liver enzymes are a known risk, and monitoring of liver function during treatment is a common recommendation by healthcare professionals.

Area of Investigation	Common Findings Reported by Studies
Adverse Events	Mostly mild and transient (headache, nausea).
Liver Function	Temporary and reversible elevation of liver enzymes observed.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Albendazol MK (FAQ)

Q: What is Albendazol MK used for other than deworming?

A: According to official product information, Albendazole is used to treat specific systemic parasitic infections, including neurocysticercosis, which affects the brain, and cystic hydatid disease, which involves cysts typically in the liver or lungs. Its use extends beyond treating common intestinal worms.

Q: How quickly does Albendazol MK start working in the body?

A: The medicine is processed by the body into its active form, albendazole sulfoxide. Regulatory studies on the drug’s pharmacokinetics show that maximal concentrations of this active form are typically achieved in the bloodstream approximately 2 to 5 hours after a dose is taken with a fatty meal. This metric reflects when the active substance is typically most concentrated in the plasma.

Q: Is Albendazol MK the same as other 'azole' medications?

A: No, Albendazol MK is chemically classified as a benzimidazole carbamate anthelmintic. While it shares the 'azole' suffix with some other drugs, this classification places it in a specialized pharmacological group that targets parasitic worms, distinct from azole medicines used to treat fungal infections.

Q: What are the known interactions between Albendazol MK and alcohol?

A: Official drug descriptions mention that using alcohol with certain medicines may cause interactions. Official drug information suggests consulting a healthcare provider for guidance regarding alcohol consumption while using this medicine.

Q: Can children of all ages use Albendazol MK?

A: Official documents state that use is generally approved for children aged 2 years and older. It is restricted for children under 2 years due to limited available clinical experience or safety data in that specific age group.

Q: What happens if I miss taking a dose of Albendazol MK?

A: Official drug resources advise against missing doses. Since guidance depends heavily on the condition being treated, any instruction on a missed dose is determined by the healthcare provider based on the individual treatment regimen.

Q: Are there different brand names for the drug Albendazol MK?

A: Yes, Albendazole is the active ingredient and generic name. It is commonly marketed under various brand names, such as Albenza and Zentel, in different regions depending on the manufacturer.

Q: Can Albendazol MK be used to treat infections outside of the digestive tract?

A: Official labeling indicates that albendazole is used to treat infections that occur outside the digestive tract. These indications include serious infections like neurocysticercosis (in the brain) and cystic hydatid disease (in organs like the liver and lungs).

Q: What research evidence exists about Albendazol MK's effectiveness in different regions?

A: Studies have examined the effectiveness of albendazole in various geographic regions, such as parts of Africa and Asia. Evidence indicates that the response to a single dose can vary significantly depending on the type of parasitic infection and the specific geographical location.

Q: Is it true that Albendazol MK can cause temporary hair loss?

A: Reversible hair loss (alopecia) has been reported in patients taking albendazole. This effect is generally described as reversible upon the cessation of treatment, according to official regulatory documents.

Q: What is the maximum amount of time the drug is typically used?

A: Treatment duration is highly variable based on the condition being treated. For complex systemic infections, regulatory regimens may involve multiple 28-day cycles with rest periods in between, potentially extending over many months.

Q: Are there any contraindications listed for older adults using Albendazol MK?

A: Official information does not list a specific contraindication for the elderly population based on age alone. However, official information suggests that caution is required in the elderly, particularly if there is an underlying risk of liver dysfunction.

Q: Do official sources mention any long-term effects of taking Albendazol MK?

A: Official documents note that serious adverse effects, such as bone marrow suppression, are generally associated with the higher doses and longer duration of treatment typically required for systemic infections. For some rare, chronic diseases, the treatment regimen may be indicated for an extended period.

Q: Does taking Albendazol MK affect the ability to drive or operate machinery?

A: Adverse reactions such as dizziness, headache, and vertigo have been reported. Official labeling advises individuals to be aware of these potential effects when performing tasks that require concentration, like driving or operating machinery.

Q: Can people with kidney conditions use Albendazol MK?

A: The drug's elimination via the kidney is minimal, and its pharmacokinetics in patients with severe kidney impairment have not been fully studied. Official guidance indicates that caution is required for individuals with kidney impairment, though dose adjustment is generally not expected to be necessary.

Q: Is Albendazol MK effective against all types of worms and parasites?

A: Albendazole is considered a broad-spectrum anti-worm medicine. However, official indications and efficacy data show that its effectiveness can vary significantly depending on the specific type of worm or parasite being treated. It is not approved for every type of parasitic infection.

Q: Can patients with pre-existing eye conditions use Albendazol MK?

A: Official information notes that blurred vision is a reported adverse effect. Additionally, a retinal examination is required before starting treatment for neurocysticercosis, indicating that official monitoring of eye health is necessary for some conditions.

Q: Is Albendazol MK used in combination with other anti-parasitic drugs sometimes?

A: Official guidelines and clinical studies support the use of albendazole in combination regimens with other anti-parasitic drugs, such as praziquantel, especially for certain complex or co-occurring infections like neurocysticercosis.

Q: Do studies suggest any specific populations might experience different side effects from Albendazol MK?

A: Official data indicates that the profile of adverse reactions can differ depending on the major disease being treated. For example, elevations in liver enzymes are noted more frequently when treating hydatid disease than when treating neurocysticercosis.

Q: Are there reports of Albendazol MK causing changes in mood?

A: Official drug information advises contacting a healthcare provider immediately if changes in behavior or mental status occur, particularly when treating neurocysticercosis. This suggests that monitoring for mood or behavioral changes is a clinical concern.

Q: Does the efficacy of Albendazol MK change based on the patient's weight?

A: Yes, for certain systemic infections like neurocysticercosis and hydatid disease, the official dosing regimen is weight-based for patients under 60 kg. This indicates that for certain uses, the dose is calculated based on body weight to help achieve therapeutic exposure.

Q: Why do some doctors recommend a repeat course of Albendazol MK?

A: Official dosing guidelines support repeat courses. For common intestinal infections, a second dose may be indicated to ensure clearance, while complex systemic conditions require specified cycles followed by drug-free intervals.

Q: Is the 'MK' part of the name Albendazol MK important?

A: Albendazole is the active drug name recognized globally. The 'MK' likely serves to designate a specific manufacturer or local trade name for the product containing the active ingredient, Albendazole.

Q: Is it necessary for the whole family to take Albendazol MK at the same time?

A: For common intestinal infections, such as pinworm, public health guidance often suggests that treatment of close contacts or the entire household be considered. This practice is aimed at minimizing the risk of re-infection among family members.

How should Albendazol MK be stored and disposed of?

Storage and Disposal of Albendazole Tablets

The official labeling mandates specific conditions to maintain product stability and protect the medicine from degradation.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Permitted excursions are 15 C to 30 C.
Protection	Store out of the sight and reach of children. Keep the container tightly closed and protected from excessive light and moisture.

Disposal Instructions

There are no explicit, universal disposal instructions provided in the core labeling. Any unused or expired Albendazole product and associated waste material must be discarded in strict accordance with local regulatory requirements for pharmaceutical waste. Environmental precautions advise against discharge into drains or water courses.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Colombia

Ecuador

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z